This comprehensive review by Sten Madsbad, published in Diabetes, Obesity & Metabolism, analyzes nine phase III and one large phase II head-to-head trials comparing six GLP-1 receptor agonists (GLP-1RAs) for type 2 diabetes management. The agents are categorized into short-acting (exenatide twice daily, lixisenatide once daily) and long-acting (liraglutide once
